On Monday, Shares of Banco Bradesco S.A. (NYSE:BBD), gained 2.10% to $9.18, as Brazil’s second largest private sector bank prepares to make a binding bid purchase of
HSBC Holding’s (HSBC) Brazilian banking unit, according to Brazilian newspaper O Estado de S. Paulo.
The process for spinning off HSBC’s Brazilian unit is in its advanced stages with the top three private sector lenders in Brazil all making bids for the business, according to Reuters.
Analysts estimate the unit could sell for between $3 billion and $4 billion.
Banco Bradesco S.A. provides banking and financial products and services to individuals, companies, and corporations and institutions. The company operates through two segments, Banking; and Insurance, Pension Plans and Capitalization Bond.
Shares of Boston Scientific Corporation (NYSE:BSX), inclined 0.28% to $17.89, during its last trading session.
Boston Scientific Corporation, has initiated a worldwide study to evaluate the rate and causes of shocks for patients implanted with the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) for primary prevention of sudden cardiac death in the setting of severely reduced cardiac function (left ventricular ejection fraction /= 35 percent). Primary prevention patients do not have a formerly documented life-threatening arrhythmic event, but are at risk of sudden cardiac death and thereby indicated to receive an implantable defibrillator. This group of patients represents the highest proportion of patients that are implanted with transvenous ICD (TV-ICDs) devices recently in the United States (U.S.) and European Union (EU).
In order to further demonstrate the usefulness of the S-ICD System in this particular patient population, the UNTOUCHED study will compare outcomes during an 18-month follow-up period to objective performance criteria derived from the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT) study. The landmark MADIT-RIT study evaluated shock rates in 1,500 patients implanted with TV-ICD devices and is one of the largest randomized trials to assess shock reduction strategies for TV-ICD devices.
The first patient enrolled in the global, multi-site, prospective, non-randomized study received an EMBLEM S-ICD System implant by Dr. Craig Barr, cardiologist at Russells Hall Hospital in Dudley, England. The study will enroll a minimum of 2,015 patients at up to 200 sites worldwide. Enrollments in the U.S. will start later this summer.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Administration, and MedSurg.
Finally, Integrated Device Technology, Inc. (NASDAQ:IDTI), ended its last trade with -0.55% loss, and closed at $23.46.
Integrated Device Technology, declared a long-term partnership with German semiconductor company ZMDI to develop energy-efficient power administration solutions. Integrating the two companies’ technologies and incorporating ZMDI’s leading-edge higher-current architectures will allow IDT to address new market segments with its award-winning power products.
The partnership comprises ZMDI’s proprietary IP within digital power, specific products, joint development programs, and popular GUI interface software.
Integrated Device Technology, Inc. designs, develops, manufactures, and markets a range of semiconductor solutions for the communications, computing, and consumer industries worldwide. It operates in two segments, Communications, and Computing and Consumer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
